Recent News
On July 14, 2025 the company announced a $1.0 million strategic investment in clinical development technology company Nurocor, citing integration potential with clinical trial automation and protocol tools.
From July 22–27, 2025 multiple investor-alert notices surfaced as law firms began investigating potential claims tied to the company’s July 14 disclosures; these notices referenced the company’s reported quarterly results and restructuring actions.
Technical Analysis
ADX: ADX at 18.84 signals no trend; this suggests directional momentum lacks strength even though shorter-term indicators show bias.
DI+/DI-: DI+ at 21.47 is increasing while DI- at 15.81 is decreasing, indicating a bullish directional bias that may support near-term upside relative to current valuation levels.
MACD: MACD at 0.15 with the MACD line above the signal line (-0.06) and MACD_trend increasing constitutes a bullish momentum signal and aligns with short-duration moving-average strength.
MRO: MRO displays a peak & reversal, which signals downside pressure from a technical overshoot while price trades above short-term targets.
RSI: RSI at 45.28 with an increasing trend shows building buying interest without overbought conditions, consistent with a modest bullish tilt for near-term swings.
Price vs. Moving Averages: Price close $15.25 sits above the 12‑day EMA ($14.90), the 20‑day average ($14.64) and the 50‑day average ($14.04), with the 200‑day average at $25.05 well above current price—this implies short-term momentum above recent averages while long-term trend remains lower than current price.
Bollinger Bands & Support: Price remains inside the 1x standard deviation upper band ($15.37) and above the super trend support at $14.33, placing immediate technical support near $14.33 and resistance near the $15.3–$16.1 band range.
Volume & Volatility: Daily volume of 3,273,704 exceeds 10‑day and 50‑day averages, indicating heightened trader attention; 42‑day beta 1.43 implies elevated short-term sensitivity versus the broader market.
Fundamental Analysis
Revenue and margins: Reported total revenue $20,363,000 reflects YoY revenue decline of 8.06% while gross margin registers 63.998% and gross profit $13,032,000. The revenue contraction contrasts with margin strength, indicating continued pricing or product-mix advantages despite lower top-line. Fiscal third-quarter adjusted results showed adjusted EBITDA of $7.4 million and adjusted diluted EPS of $0.45. The company recorded a one-time non-cash impairment charge driving a GAAP net loss.
Profitability measures: EBIT $2,995,000 and EBITDA $5,313,000 produce an EBIT margin of 14.708%, which sits below the industry peer mean of 22.62% and below the industry peer median of 30.793%, but above the industry peer low. QoQ EBIT margin improved by 21.654% and YoY improved by 45.078%, indicating recent margin recovery against a depressed prior period.
Cash and leverage: Cash $26,950,000 and cash and short-term investments $28,450,000 yield a cash ratio of 2.81 and current ratio of 5.11, both above the industry peer mean levels provided. Total debt measured $719,000 produces a debt-to-assets of 0.54% and debt-to-equity of 0.58%, reflecting a conservatively capitalized balance sheet that supports flexibility during restructuring.
Cash flow and valuation metrics: Operating cash flow $8,144,000 and free cash flow $7,054,000 produce a free cash flow yield of 2.04% and a cash-flow-to-earnings relationship near parity for adjusted metrics. Market multiples show a PE ratio of 53.93 and an EVR of 15.60; forward P/E near 120 reflects near-term earnings compression when calculated on GAAP guidance differences. The current valuation as determined by WMDST: under-valued.
Earnings detail and adjustments: GAAP net loss $67,317,000 reflects the $77.2 million non-cash impairment disclosed with the quarter; adjusted results (adjusted EBITDA and adjusted EPS $0.45) present a materially different operational view and produced an EPS surprise versus the estimate.
MOST-RECENT QUARTERLY REPORT
| REPORT PERIOD ENDING: | 2025-05-31 |
| REPORT DATE: | 2025-07-14 |
| NEXT REPORT DATE: | 2025-09-29 |
| CASH FLOW | Begin Period Cash Flow | $ 11.0 M |
| Operating Cash Flow | $ 8.1 M | |
| Capital Expenditures | $ -1.09 M | |
| Change In Working Capital | $ 1.6 M | |
| Dividends Paid | — | |
| Cash Flow Delta | $ 16.0 M | |
| End Period Cash Flow | $ 26.9 M | |
| INCOME STATEMENT | REVENUE | |
| Total Revenue | $ 20.4 M | |
| Forward Revenue | $ -391.72 K | |
| COSTS | ||
| Cost Of Revenue | $ 7.3 M | |
| Depreciation | $ 2.3 M | |
| Depreciation and Amortization | $ 2.3 M | |
| Research and Development | $ 1.2 M | |
| Total Operating Expenses | $ 17.4 M | |
| PROFITABILITY | ||
| Gross Profit | $ 13.0 M | |
| EBITDA | $ 5.3 M | |
| EBIT | $ 3.0 M | |
| Operating Income | $ 3.0 M | |
| Interest Income | $ 170.0 K | |
| Interest Expense | — | |
| Net Interest Income | $ 170.0 K | |
| Income Before Tax | $ -74.04 M | |
| Tax Provision | $ -6.73 M | |
| Tax Rate | 9.085 % | |
| Net Income | $ -67.32 M | |
| Net Income From Continuing Operations | $ -67.32 M | |
| EARNINGS | ||
| EPS Estimate | $ 0.25 | |
| EPS Actual | $ 0.45 | |
| EPS Difference | $ 0.20 | |
| EPS Surprise | 80.0 % | |
| Forward EPS | $ 0.26 | |
| BALANCE SHEET | ASSETS | |
| Total Assets | $ 134.4 M | |
| Intangible Assets | $ 73.6 M | |
| Net Tangible Assets | $ 50.2 M | |
| Total Current Assets | $ 51.8 M | |
| Cash and Short-Term Investments | $ 28.4 M | |
| Cash | $ 26.9 M | |
| Net Receivables | $ 14.8 M | |
| Inventory | — | |
| Long-Term Investments | $ 430.0 K | |
| LIABILITIES | ||
| Accounts Payable | $ 1.7 M | |
| Short-Term Debt | — | |
| Total Current Liabilities | $ 10.1 M | |
| Net Debt | — | |
| Total Debt | $ 719.0 K | |
| Total Liabilities | $ 10.6 M | |
| EQUITY | ||
| Total Equity | $ 123.8 M | |
| Retained Earnings | $ -33.68 M | |
| VALUATION & PER-SHARE METRICS | EQUITY & PER-SHARE METRICS | |
| Book Value Per-Share | $ 6.15 | |
| Shares Outstanding | 20.116 M | |
| Revenue Per-Share | $ 1.01 | |
| VALUATION | Market Capitalization | $ 345.3 M |
| Enterprise Value | $ 317.6 M | |
| Enterprise Multiple | 59.776 | |
| Enterprise Multiple QoQ | -46.822 % | |
| Enterprise Multiple YoY | -76.959 % | |
| Enterprise Multiple IPRWA | high: 187.312 median: 129.932 mean: 124.276 SLP: 59.776 low: -61.072 |
|
| EV/R | 15.596 | |
| CAPITAL STRUCTURE | ||
| Asset To Equity | 1.085 | |
| Asset To Liability | 12.698 | |
| Debt To Capital | 0.006 | |
| Debt To Assets | 0.005 | |
| Debt To Assets QoQ | 35.443 % | |
| Debt To Assets YoY | 25.587 % | |
| Debt To Assets IPRWA | high: 0.603 mean: 0.052 median: 0.01 low: 0.008 SLP: 0.005 |
|
| Debt To Equity | 0.006 | |
| Debt To Equity QoQ | 38.333 % | |
| Debt To Equity YoY | 28.256 % | |
| Debt To Equity IPRWA | high: 1.265 mean: 0.086 median: 0.012 SLP: 0.006 low: -1.054 |
|
| PRICE-BASED VALUATION | ||
| Price To Book (P/B) | 2.79 | |
| Price To Book QoQ | -8.991 % | |
| Price To Book YoY | -45.952 % | |
| Price To Book IPRWA | high: 11.276 mean: 6.384 median: 6.06 SLP: 2.79 low: -6.059 |
|
| Price To Earnings (P/E) | 53.925 | |
| Price To Earnings QoQ | -72.003 % | |
| Price To Earnings YoY | -82.664 % | |
| Price To Earnings IPRWA | high: 163.345 median: 117.241 mean: 112.13 SLP: 53.925 low: -99.343 |
|
| PE/G Ratio | 1.194 | |
| Price To Sales (P/S) | 16.958 | |
| Price To Sales QoQ | -34.531 % | |
| Price To Sales YoY | -66.314 % | |
| Price To Sales IPRWA | high: 93.726 median: 49.584 mean: 48.438 SLP: 16.958 low: 0.843 |
|
| FORWARD MULTIPLES | ||
| Forward P/E | 120.097 | |
| Forward PE/G | 2.659 | |
| Forward P/S | -881.538 | |
| EFFICIENCY | OPERATIONAL | |
| Operating Leverage | -1.131 | |
| ASSET & SALES | ||
| Asset Turnover Ratio | 0.121 | |
| Asset Turnover Ratio QoQ | 7.689 % | |
| Asset Turnover Ratio YoY | 26.449 % | |
| Asset Turnover Ratio IPRWA | high: 0.368 SLP: 0.121 mean: 0.112 median: 0.101 low: 0.0 |
|
| Receivables Turnover | 1.302 | |
| Receivables Turnover Ratio QoQ | -14.959 % | |
| Receivables Turnover Ratio YoY | -18.334 % | |
| Receivables Turnover Ratio IPRWA | high: 3.6 SLP: 1.302 mean: 1.163 median: 1.006 low: 0.882 |
|
| Inventory Turnover | — | |
| Inventory Turnover Ratio QoQ | — | |
| Inventory Turnover Ratio YoY | — | |
| Inventory Turnover Ratio IPRWA | — | |
| Days Sales Outstanding (DSO) | 70.07 | |
| CASH CYCLE | ||
| Cash Conversion Cycle Days (CCC) | — | |
| Cash Conversion Cycle Days QoQ | — | |
| Cash Conversion Cycle Days YoY | — | |
| Cash Conversion Cycle Days IPRWA | — | |
| CAPITAL DEPLOYMENT | ||
| Cash Conversion Ratio | 0.489 | |
| CapEx To Revenue | -0.054 | |
| CapEx To Depreciation | -0.47 | |
| CAPITAL, LIQUIDITY & COVERAGE | CAPITAL STRUCTURE | |
| Total Capital | $ 123.8 M | |
| Net Invested Capital | $ 123.8 M | |
| Invested Capital | $ 123.8 M | |
| Net Tangible Assets | $ 50.2 M | |
| Net Working Capital | $ 41.6 M | |
| LIQUIDITY | ||
| Cash Ratio | 2.808 | |
| Current Ratio | 5.111 | |
| Current Ratio QoQ | 16.997 % | |
| Current Ratio YoY | -57.342 % | |
| Current Ratio IPRWA | high: 6.468 SLP: 5.111 median: 4.605 mean: 4.454 low: 0.014 |
|
| Quick Ratio | — | |
| Quick Ratio QoQ | — | |
| Quick Ratio YoY | — | |
| Quick Ratio IPRWA | — | |
| COVERAGE & LEVERAGE | ||
| Debt To EBITDA | 0.135 | |
| Cost Of Debt | 88.19 % | |
| Interest Coverage Ratio | 4.076 | |
| Interest Coverage Ratio QoQ | 10.435 % | |
| Interest Coverage Ratio YoY | 59.309 % | |
| Interest Coverage Ratio IPRWA | high: 23.544 median: 7.727 mean: 6.316 SLP: 4.076 low: -10.0 |
|
| Operating Cash Flow Ratio | -6.202 | |
| TIMING / LIQUIDITY | ||
| Days Payables Outstanding (DPO) | 14.068 | |
| DIVIDENDS | ||
| Dividend Coverage Ratio | — | |
| Dividend Payout Ratio | — | |
| Dividend Rate | — | |
| Dividend Yield | — | |
| PERFORMANCE | GROWTH | |
| Asset Growth Rate | -33.296 % | |
| Revenue Growth | -9.223 % | |
| Revenue Growth QoQ | -149.755 % | |
| Revenue Growth YoY | -806.202 % | |
| Revenue Growth IPRWA | high: 33.14 % median: 5.293 % mean: 3.979 % SLP: -9.223 % low: -46.267 % |
|
| Earnings Growth | 45.161 % | |
| Earnings Growth QoQ | -96.774 % | |
| Earnings Growth YoY | -280.644 % | |
| Earnings Growth IPRWA | high: 675.0 % SLP: 45.161 % median: 13.218 % mean: 7.332 % low: -275.0 % |
|
| MARGINS | ||
| Gross Margin | 63.998 % | |
| Gross Margin QoQ | 9.363 % | |
| Gross Margin YoY | -10.479 % | |
| Gross Margin IPRWA | high: 96.642 % median: 77.1 % mean: 75.763 % SLP: 63.998 % low: 13.884 % |
|
| EBIT Margin | 14.708 % | |
| EBIT Margin QoQ | 21.654 % | |
| EBIT Margin YoY | 45.078 % | |
| EBIT Margin IPRWA | high: 37.363 % median: 30.793 % mean: 22.62 % SLP: 14.708 % low: -171.354 % |
|
| Return On Sales (ROS) | 14.708 % | |
| Return On Sales QoQ | 21.654 % | |
| Return On Sales YoY | 45.078 % | |
| Return On Sales IPRWA | high: 37.363 % median: 30.793 % mean: 22.743 % SLP: 14.708 % low: -171.354 % |
|
| CASH FLOW | ||
| Free Cash Flow (FCF) | $ 7.1 M | |
| Free Cash Flow Yield | 2.043 % | |
| Free Cash Flow Yield QoQ | 150.675 % | |
| Free Cash Flow Yield YoY | 303.755 % | |
| Free Cash Flow Yield IPRWA | high: 4.882 % median: 2.331 % SLP: 2.043 % mean: 1.454 % low: -22.063 % |
|
| Free Cash Growth | 48.881 % | |
| Free Cash Growth QoQ | -115.428 % | |
| Free Cash Growth YoY | 380.828 % | |
| Free Cash Growth IPRWA | high: 297.281 % SLP: 48.881 % median: -37.992 % mean: -44.894 % low: -350.863 % |
|
| Free Cash To Net Income | -0.105 | |
| Cash Flow Margin | -308.545 % | |
| Cash Flow To Earnings | 0.933 | |
| VALUE & RETURNS | ||
| Economic Value Added | $ 0.04 | |
| Return On Assets (ROA) | -40.095 % | |
| Return On Assets QoQ | -2698.509 % | |
| Return On Assets YoY | -2570.425 % | |
| Return On Assets IPRWA | high: 4.32 % median: 3.021 % mean: 2.333 % low: -27.619 % SLP: -40.095 % |
|
| Return On Capital Employed (ROCE) | 2.411 % | |
| Return On Equity (ROE) | -0.544 | |
| Return On Equity QoQ | -3452.959 % | |
| Return On Equity YoY | -3234.582 % | |
| Return On Equity IPRWA | high: 0.052 median: 0.037 mean: 0.026 low: -0.35 SLP: -0.544 |
|
| DuPont ROE | -42.971 % | |
| Return On Invested Capital (ROIC) | 2.2 % | |
| Return On Invested Capital QoQ | -119.061 % | |
| Return On Invested Capital YoY | -270.675 % | |
| Return On Invested Capital IPRWA | high: 5.266 % median: 2.875 % mean: 2.469 % SLP: 2.2 % low: -12.189 % |
|